Daiichi Sankyo Inc. — Sponsor Intelligence | 46 EU Trials

Filter these 46 trials by condition, phase, country and more.

Open in Search →

46 Registered trials

20 Recruiting

24 Completed trials

20 Countries active

35 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase III: 15 Phase II/III: 2 Phase II: 7 Phase I/II: 5 Phase I: 5 Phase I (Other): 6 Phase I (FiH): 2 Other: 4

Oversight events:

2 serious breaches 14 temporary halts 4 urgent safety measures 1 corrective measure across 7 trials

View oversight register →

100%

24 of 24 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 8 Ovarian cancer 5 Breast cancer metastatic 4 HER2 positive breast cancer 4 Endometrial cancer 3 Non-small cell lung cancer metastatic 3 Colorectal cancer 3 Neoplasm 2 HER2 positive gastric cancer 2 Metastatic gastric cancer 2 Breast cancer 2 Small cell lung cancer extensive stage 2

Top IMPs

TRASTUZUMAB DERUXTECAN 10 DATOPOTAMAB DERUXTECAN 6 IFINATAMAB DERUXTECAN 5 PEMBROLIZUMAB 4 CISPLATIN 3 PATRITUMAB DERUXTECAN 3 VALEMETOSTAT TOSILATE 3 CARBOPLATIN 2 QUIZARTINIB DIHYDROCHLORIDE 2 RALUDOTATUG DERUXTECAN 2 TRASTUZUMAB EMTANSINE 2 BEVACIZUMAB 1

All trials

46 total

First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors Pending

2025-521173-13-00 Phase I 2 countries
A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. Pending

2025-522595-87-00 Phase I (FiH) 2 countries DS-3790A
Phase 1 trial of valemetostat and darolutamide in mCRPC Recruiting

2025-522512-16-00 Phase I (Other) 3 countries
Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting

2024-519444-33-00 Phase III 7 countries CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; TRASTUZUMAB DERUXTECAN
First-in-Human trial of DS9051b in participants with advanced solid tumors Recruiting

2025-521886-28-00 Phase I 1 country
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Phase II/III 11 countries CARBOPLATIN; CISPLATIN; DATOPOTAMAB DERUXTECAN; GEMCITABINE
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting

2023-507936-20-00 Phase III 15 countries CYTARABINE; DAUNORUBICIN HYDROCHLORIDE; IDARUBICIN HYDROCHLORIDE; QUIZARTINIB DI…
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Phase III 13 countries IFINATAMAB DERUXTECAN
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Phase III 9 countries TRASTUZUMAB DERUXTECAN
Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial. Recruiting

2024-516625-31-00 Phase I (Other) 2 countries
A Phase 1b/2, Study of I-DXd in Combination with Atezolizumab with or without Carboplatin in First-line ES‑SCLC Recruiting

2023-509629-36-00 Phase I/II 2 countries IFINATAMAB DERUXTECAN
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Phase III 14 countries BEVACIZUMAB; TRASTUZUMAB DERUXTECAN
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph… Recruiting

2023-509630-19-00 Phase III 11 countries IFINATAMAB DERUXTECAN
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus … Recruiting

2024-513122-27-00 Phase III 12 countries CISPLATIN; FLUOROURACIL; OXALIPLATIN; PEMBROLIZUMAB; TRASTUZUMAB; TRASTUZUMAB DE…
First-in-human Trial of DS-2243a in Participants with Advanced Solid Tumors Recruiting

2024-512058-11-00 Phase I 3 countries
First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting

2023-507937-14-00 Phase I (FiH) 3 countries DS-3939A
Pan-tumor Study of I-DXd in Subjects with Recurrent or Metastatic Solid Tumors Recruiting

2023-509632-26-00 Phase I/II 9 countries IFINATAMAB DERUXTECAN
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Phase II 6 countries TRASTUZUMAB DERUXTECAN
Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting

2023-507641-29-00 Phase II 8 countries PATRITUMAB DERUXTECAN
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can… Recruiting

2023-507914-28-00 Phase II/III 9 countries RALUDOTATUG DERUXTECAN
A Master rollover study to provide continued access to, and assess, long term safety of the study drugs. Recruiting

2023-506330-73-00 Phase III 4 countries TRASTUZUMAB DERUXTECAN
DS-1103a Combination Therapy First-in-human (FIH) Study Recruiting

2023-503965-48-00 Phase I 3 countries
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended

2024-513307-13-00 Phase II 5 countries RALUDOTATUG DERUXTECAN
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Phase III 13 countries DATOPOTAMAB DERUXTECAN; PEMBROLIZUMAB

Showing 1–24 of 46 trials

← All sponsors A–Z